

## Brian Strom

---

### SECTION A: INDIVIDUAL INFORMATION

#### A.1. Personal information

<b>Name</b>	Brian L Strom, MD, MPH
<b>Post or Position</b>	University Professor, Chancellor of Biomedical and Health Sciences
<b>Employer , Research Institution or Affiliation</b>	Rutgers University, United States.

#### A.2. Short Biography

BRIAN L. STROM, M.D., M.P.H. is the Chancellor of Rutgers Biomedical and Health Sciences at Rutgers University, the State University of New Jersey. He was previously George S. Pepper Professor of Public Health and Preventive Medicine, Executive Vice Dean for Institutional Affairs, and Professor of Biostatistics and Epidemiology, of Medicine, and of Pharmacology, all at the Perelman School of Medicine of the University of Pennsylvania. He formerly was Founding Chair of the Department of Biostatistics and Epidemiology and Founding Director of the Center for Clinical Epidemiology and Biostatistics, which now includes over 550 faculty, research and support staff, and trainees.

Although Dr. Strom's interests span many areas of clinical epidemiology, his major research interest is in the field of pharmacoepidemiology, i.e., the application of epidemiologic methods to the study of drug use and effects. He is editor of the field's major text (now in its fifth edition), and is Editor-in-Chief for Pharmacoepidemiology and Drug Safety, the official journal of the International Society for Pharmacoepidemiology, one of a number of societies he served as President. In addition to writing more than 575 papers, he has been principal investigator for more than 275 grants, including over \$114 million in direct costs alone. He has been invited to more than 390 talks outside his local area, including being the keynote speaker for numerous international meetings. Dr. Strom has been a consultant to NIH, FDA, CDC, USP, AAMC, JCAHO, foreign governments, most major pharmaceutical manufacturers, and many law firms. Among many other honors, Dr. Strom is a member of the Institute of Medicine, and its Drug Forum.

## SECTION B: DISCLOSURES

### **B.1. Financial Interests**

*Please provide information on financial interests that could be perceived to influence the responsibilities and decision making process of the Independent Panel. This should include financial relationships with GSK and other pharmaceutical or biotechnology companies within the last 3 years. It should include:*

- *Board memberships*
- *Consultancies*
- *Employments*
- *Grants/grants pending*
- *Patents (planned, pending or issued)*
- *Royalties*
- *Stocks or shares (including options)*

**Answer:** Within the last three years I've consulted for the following companies: Abbott, AGI Pharm, Amgen, Bristol-Myers Squibb, Endo, GSK, Lexicon, Lundbeck, Novartis, Orexigen, Pfizer, PhRMA, Pierre Fabre Dermatologie, Standard Homeopathic Co., Teva, and Vivus. I've received grant funding from AstraZeneca/Bristol-Myers Squibb, Takeda Pharmaceuticals, and Kaiser Permanente. The University of Pennsylvania Pharmacoepidemiology Training Program received donations from Sanofi-Aventis, Pfizer, and Teva. I also own stock options in Express Scripts.

### **B.2 Other Real or Potential Conflicts of Interest**

*Please provide any other (e.g. non-financial) real or potential conflicts of interest that could be perceived to influence the responsibilities and decision making process of the Independent Panel. For example potential biases based on pre-existing personal views, academic or commercial competition, personal relationships or institutional affiliations.*

**Answer:** None